Halozyme Therapeutics (NASDAQ:HALO) fell 14% after confirming on Thursday that it made an €11 per share bid for Evotec (EVO).
Today we might actually see the end of Chapter 3, a section of the game that's about as long as the first two areas combined.
This is not a drill, readers! Black Friday deals are officially here! We’ve been prepping for Black Friday sales all month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback